医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Peptide Discovery Collaboration Agreement with Merck & Co., Inc

2015年05月01日 PM04:59
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) today announced a multi-target discovery and optimization collaboration with Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through a subsidiary. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocylic/constrained peptides against multiple targets of interest selected by Merck & Co. Inc. Merck & Co. Inc. will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration and retains an option to nonexclusively license the PDPS technology at a future date. PeptiDream will receive an undisclosed upfront payment, research funding and will be eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.

“We are very excited to collaborate with Merck & Co. Inc. PeptiDream has emerged as a major player in the constrained peptide space,” said Kiichi Kubota, CEO of PeptiDream Inc. “Our unique PDPS platform allows us to rapidly build highly diverse constrained peptide libraries, largely tailored to the individual target, leading to the rapid identification of chemically diverse hits, which can then be quickly assessed for the desired biological activity profiles. No other technology can create such a chemically and structurally diverse set of functional and developable leads in such a short period of time”.

In the past five years, PeptiDream has established funded discovery collaborations with many leading pharmaceutical companies, such as Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, as well as a strategic collaboration with Ipsen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Code Corporation Expands Into Australian Healthcare Market, Signs HPA as New Channel Partner
  • Asahi Kasei and Nara Medical University Confirm 226 nm UVC LED Efficacy Against SARS-CoV-2 and Verify Reduced Effect on Animal Skin Cells
  • HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic
  • Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
  • アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す